Last updated: July 31, 2025
Introduction
China Patent CN103626739, titled “A Novel Pharmaceutical Composition and Its Use”, represents an innovative contribution within the biomedical field, particularly in the development of therapeutic agents. This patent appears to focus on novel chemical entities, formulations, or methods intended for clinical application. A comprehensive understanding of its scope, claims, and the broader patent landscape is essential for stakeholders interested in the competitive positioning, licensing opportunities, or potential infringement risks related to the patent.
Patent Overview and Technical Field
CN103626739 was filed as part of China's burgeoning pharmaceutical innovation sector, reflecting a trend toward developing new chemical entities (NCEs) or optimized formulations capable of addressing unmet medical needs. The patent specifically targets therapeutic compositions, potentially for indications such as cancer, infectious diseases, or chronic conditions—dependent on the chemical structure or method claims detailed within.
The patent application belongs predominantly to the technical fields of medicinal chemistry, pharmaceutical compositions, and treatment methods. The detailed description likely emphasizes novel compounds or combinations with enhanced pharmacokinetic or pharmacodynamic properties.
Scope of the Patent
The patent's scope is primarily delineated through the claims, which delimit the legal boundaries of the invention. Understanding the scope involves analyzing both independent and dependent claims.
1. Independent Claims
The independent claims in CN103626739 are designed to define the broadest scope of the patent’s protection. Based on standard pharmaceutical patent strategies, these claims typically cover:
- The chemical composition itself, including specific chemical structures or classes of compounds.
- Methods of producing the compound or composition.
- Therapeutic methods employing the composition, such as treatment or prophylaxis for specific diseases.
For example, if the compound belongs to a novel chemical class with potential anticancer activity, the independent claims might encompass structural formulas with various substituents, provided they fall within the claimed chemical genus.
2. Dependent Claims
Dependent claims narrow the scope by specifying particular embodiments, such as:
- Specific isomers, derivatives, or salts of the main compound.
- Particular dosage forms or dosing regimens.
- Combination with other pharmaceutical agents.
- Methods of synthesis or purification.
This layered claim structure aims to safeguard core innovations while providing fallback positions for enforcement and licensing.
Claims Analysis
Chemical Structure and Novelty
CN103626739's claims likely include a novel core structure, possibly a heterocyclic framework or a new linker, designed to confer unique biological activity or improved pharmacokinetics. The claims possibly define the compound through Markush structures—a generic chemical depiction encompassing multiple variants.
Therapeutic Application
Claims probably extend to the use of these compounds for specific medical indications, which is crucial for strategic patent protection. Focus areas may include treating cancers, infections, or metabolic disorders—monitored by the description’s emphasis on biological activity.
Method of Use and Formulation
Another significant aspect involves claims on therapeutic methods—administering the compositions, dosages, and formulations. These claims enable patent owners to assert rights over specific treatment protocols or drug delivery systems.
Patent Landscape and Competitor Context
Existing Patents and Prior Art
The patent landscape surrounding CN103626739 encompasses both domestic and international patents. Similar chemical classes registered in prior Chinese patents, such as CN102xxxxxx or CN105xxxxxx, may constitute prior art, challenging the novelty or inventive step of the current patent.
Internationally, parallel filings—such as PCT applications—may exist, reflecting the applicant's broader strategy. Key considerations include:
- Overlapping chemical structures with existing patents (e.g., prior art in the same activity spectrum).
- Known chemical scaffolds that the current patent modifies or improves.
- Existing treatment methods or formulations covered by prior art.
The determination of patent novelty and inventive step hinges on this landscape. Effective freedom-to-operate (FTO) analysis depends on detailed prior art searches, considering both Chinese and global patent documents.
Patent Family and Filing Strategy
CN103626739 likely belongs to a patent family that includes filings in jurisdictions like the US (USPTO), Europe (EPO), and Japan, indicating global commercialization ambitions. The timing of these filings reveals strategic priorities—whether to block competitors or secure broad protection.
Legal Status and Enforcement Considerations
As of the latest public data, CN103626739's legal status remains active, with no evidence of opposition or invalidation actions. Enforcement potential depends on:
- The patent’s validity for the claims as granted.
- The scope aligning with the patent owner’s patent portfolio.
- The presence of infringing compounds or methods on the market.
Given the rigorous patent examination in China, the granted scope provides a significant barrier for competitors seeking to develop similar compounds without license.
Innovation and Competitive Advantage
The patent's strength originates from:
- The novelty of the chemical structure or composition.
- Demonstrated biological activity or improved pharmacokinetics.
- Specific claims around therapeutic use, which extend exclusivity into particular medical fields.
If it successfully claims a new chemical entity with clinical advantages, it offers a competitive edge—especially in the rapidly growing Chinese pharmaceutical market.
Potential Challenges and Workarounds
- Prior Art: Similar existing patents may limit scope; inventive step must be sufficiently argued.
- Claim Breadth: Broad claims risk higher invalidation; narrower claims focused on specific compounds or uses are easier to enforce.
- Patent Term and Data Exclusivity: As a newer patent, CN103626739 is likely to provide patent protection until at least 2033, aligning with data exclusivity periods if applicable.
Conclusion
CN103626739 spans a significant scope covering novel chemical entities and their therapeutic uses. Its strength depends on the novelty of the claimed compounds, specific use cases, and strategic claim drafting. In the landscape of Chinese pharmaceutical patents, it anchors a comprehensive protective position for its holders, possibly enabling licensing or collaborations in China and abroad.
Key Takeaways
- The patent’s strength lies in its potentially broad chemical and therapeutic claims, offering robust protection for innovative compounds.
- Thorough prior art and patent landscape analysis are essential to assess infringement risk and freedom-to-operate.
- Strategic claim drafting—combining broad genus claims with narrow specific embodiments—maximizes enforceability.
- The patent is positioned within China’s expanding pharmaceutical innovation ecosystem, with significant prospects for commercialization.
- Ongoing patent monitoring and potential opposition proceedings could influence the patent’s enforceability over time.
FAQs
1. What is the primary innovation covered by CN103626739?
It likely covers a novel chemical compound or class with therapeutic properties and specific methods of use or formulations, although the precise chemical structures and indications require detailed claim analysis.
2. How does this patent compare to similar international patents?
It may be part of a global patent family, with prioritized filings to secure protection in China, possibly building upon or overlapping with existing patents in other jurisdictions.
3. Can the scope of CN103626739 be broadened or narrowed?
Broad claims can be strategically narrowed to improve robustness against prior art, while narrow claims provide stronger enforcement for specific embodiments.
4. How do prior patents in the same field impact CN103626739?
Prior patents might limit the novelty or inventive step, influencing the patent’s validity and enforcement, highlighting the importance of thorough FTO analyses.
5. What are the implications for pharmaceutical companies wanting to develop similar compounds?
They must analyze the patent claims carefully to avoid infringement and consider licensing or designing around the patented compounds or methods.
References
- Official Chinese patent database (SIPO/SQIP) and patent documents.
- Patent analysis reports and prior art searches related to CN103626739.
- Chinese patent examination guidelines and pharmaceutical patent strategies.
